




RefluxStop™ addressable market


According to a recently published global study in Nature⁶ medical journal, there are more than 1 Billion people suffering from reflux disease. The awareness of complications from PPI use is growing, and these complications are more dangerous than previously anticipated, leading to serious diseases and even death. Most dangerously, the cancer risk with acid reflux remains during drug therapy, and combined with the complication profile, the market for surgical procedures is expected to grow.

Due to the many complications associated with currently available procedures, only 248,000 patients opt for anti-reflux surgical procedures each year of which over 150,000 were in the North America and European countries. Implantica's new device treats acid reflux without affecting the food passageway at all and has the potential to be a paradigm shift in acid reflux treatment. Once a viable treatment is available, two third-party sources in average (BIS Research expect the surgical treatment addressable market to grow substantially and expect the addressable market of GERD procedures to expand by about 25 percent annually to reach 1.2 million operations yearly by 2026.



With up to 40 %⁷ of GERD sufferers not satisfied with PPI treatment outcomes, based on excellent current patient outcomes, RefluxStop™ has the potential to significantly improve quality of life for millions of patients in Europe, North America and rest of the world. Even with most conservative estimates for market penetration rates, RefluxStop has the potential to become a multi-billion dollar business. In addition, when it is proven that RefluxStop™ prevents the incidence of esophageal cancer – which causes the loss of about 48,000 lost lives annually in the EU and US alone, the number of sufferers is so large that the market has the possibility to reach up to 10 million surgeries each year.

Target Patient Population:



Even if only a 10% of anti-reflux surgery eligible gets RS, the market opportunity is huge.

¹ <https://www.nature.com/articles/s41598-020-62795-1>

² <https://biomedgrid.com/pdf/AJBSR.MS.ID.000619.pdf>

³ <https://www.nature.com/articles/s41598-020-62795-1>

⁴ <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3801364/>

*Key Assumptions

** r-GERD means Refractory GERD

⁵ iData Research Report for Implantica

⁶ Nirwan JS, Hasan SS, Babar ZU, Conway BR, Ghori MU. Global Prevalence and Risk Factors of Gastro-oesophag-eal Reflux Disease (GORD): Systematic Review with Meta-analysis. Sci Rep. 2020 Apr 2;10(1):5814. doi: 10.1038/s41598-020-62795-1. PMID: 32242117; PMCID: PMC7118109.

⁷ Karamanolis, G. P., & Sifrim, D. (2013). Patients with refractory gastroesophageal reflux disease: diagnostic tools. Annals of gastroenterology, 26(1), 6–10



Implantica in brief

Bringing advanced technology into the body – RefluxStop™

Implantica's lead product, RefluxStop™, is a CE-marked implant for the prevention of gastroesophageal reflux disease (GERD) that will potentially create a paradigm shift in anti-reflux treatment as supported by successful clinical trial results.



RefluxStop™

RefluxStop™ treats the cause of acid reflux and is based on a completely different method than existing surgical treatments

- Provides better results without complications often associated with existing GERD treatments
- Currently being commercialized in Europe
- On path toward US market approval

17% EU

19% US

percent of population affected weekly by acid reflux

RefluxStop™ has the potential to create a paradigm shift in the treatment of GERD
→ **Has all the attributes to become the new standard of care, supported by excellent clinical trial results and KOL feedback**

RefluxStop™

RefluxStop™ fills an unmet medical need

400 million

GERD impacts over 400 million people daily.

almost **40%**

of patients with persistent GERD symptoms continue to have measurable 24-hour pH reflux episodes despite daily PPI use.

USD 15-20 billion

USD 15-20 billion – annual direct and indirect costs of GERD in the US.

48,000

Approximately 48,000 deaths occur annually in the EU and US alone due to adenocarcinoma in the lower esophagus.



The size of the RefluxStop™ is 25 millimeters (1 inch).

”

Successfully treated patients are our core focus.

